Nuclear medicine at vet clinics just got established within the last 5 years using Strontium on the end of a rod to treat small cancers around they eyes and nose. These clinics are set up to deal with a radioactive material. So, the hard work has been done.

The RDGL injectable radioactive material can more rapidly be deployed now due to this.

https://www.google.com/search?source=hp&ei=YIdYW9fMF8LHzwKMmITgDw&q=strontium+vet+clinics&oq=strontium+vet+clinics&gs_l=psy-ab.3...720.3618.0.3702.23.19.0.0.0.0.198.1991.0j15.16.0..2..0...1.1.64.psy-ab..7.14.1786.0..0j0i131k1j0i10k1j0i22i30k1j33i21k1.139.MA8fxT-SHBU

Looks to me entire float taken away last 10 days knowing this news was coming

lot of comps in the $500M range


Competitive Landscape
During examination of comparable
companies,
we looked at medical device companies
that
have
radio
logy therapy products
in cancer
.
Companies like
Sirtex,
Oncosil Medical, Oncura, Isoray,
Elekta
and BTG.
As AMIC aims to sell its product first
on the veterinary market for cancer therapy
for cats and dogs, we also took into account various
animal health companies that have ca
ncer
products in development or already on the market.
As mentioned before, the marketpotential for
animal cancer therapy is considerable and growing fast.
Accuray
(ARAY)
Accuray
is a radiation oncology company. The Company develops, m
anufactures, sells and
supports treatment solutions. Its suite of products includ
es the CyberKnife Systems and the
To m o T h e r a p y S y s t e m s . I t s t e c h n o l o g i e s , t h e C y b e r K n i f
e a n d To m o T h e r a p y S y s t e m s , a r e d e
signed
to deliver treatments, including radiosurgery, stereotactic b
ody radiation therapy, intensity
modulated radiation therapy (IMRT), image guided radi
ation therapy (IGRT) and adaptive radiation
therapy. Its principal radiosurgery products, the CyberKni
fe Systems are robotic full
-
body
radiosurgery system designed to treat tumors anywhere in the
body non
-
invasively, which include
the CyberKnife M6 Series with configuration options of fix
ed collimators plus iris variable aperture
collimator (FI), fixed col
limators plus the InCise MLC (FM) and fixed collimators plus iris
variable
aperture collimator and the InCise MLC (FIM). The TomoT
herapy Systems include the TomoTherapy
H Series with configuration options of TomoH, TomoHD and
TomoHDA. The Company has
opera
tions in Americas, Europe, Middle East, India, Africa a
nd Japan.
The CyberKnife Systems are
robotic systems that deliver stereotactic radiosurgery
(SRS) and stereotactic body radiation therapy
(SBRT) and are used to treat multiple types of cancer an
d tumor
s throughout the body. The
CyberKnife Systems track, detect and correct tumor a
nd patient movement in real
-
time during the
procedure. Treatment with the CyberKnife Systems requires
no anesthesia, and can be performed




24
ADVANCED MEDICAL ISOTOPE CORP
in one to five staged treatment session
s on an outpatient basis. The CyberKnife Systems deliver
treatments for intra
-
and extra
-
cranial disease sites throughout the body, including
prostate, lung,
brain, spine, liver, pancreas and kidney.
The CyberKnife M6 Series System is available with the
In
Cise multi
-
leaf collimator (InCise MLC), which is available on a robotic plat
form. Its configurations
of CyberKnife Systems include the CyberKnife M6 Series
with configurations of FI, FM and FIM and
CyberKnife VSI System. The CyberKnife M6 Series syste
m in
cludes disease
-
specific tracking and
treatment delivery solutions for brain, spine, lung and pr
ostate tumors, treatment speed
improvements and options to configure the treatment ro
om. The CyberKnife VSI System comes
with fixed collimators or an optional Ir
is collimator.
BTG plc
(BTG.L)
BTG plc is a specialist healthcare company. The Company
operates in three business segments:
Interventional Medicine (IM) (oncology, vascular and pulmonology
products), Specialty
Pharmaceuticals (antidote products) and Licens
ing (royalties from licensed assets). The Company's
Interventional Medicine segment offers a portfolio of inter
ventional medicine products that are
designed to advance the treatment of liver tumors, advanced
emphysema, severe blood clots and
varicose veins
. The Company's Specialty Pharmaceuticals segment offe
rs a portfolio of antidote
products that alleviate toxicity and treat rare conditions.
The Company's Licensing segment
receives royalties relating to the sales of products th
at are subject to intellectu
al property and
license agreements between the Company and various par
tners. The Company's subsidiaries
include BTG International (Holdings) Ltd, Provensis Ltd, BTG
International Ltd and BTG Employee
Share Schemes Ltd, among others.
Isoray
(ISR)
Isoray
develops, manufactures and sells isotope
-
based medical products and devices for the
treatment of cancer and other malignant diseases. The Comp
any is engaged in treatment for all
solid tumors using Cesium
-
131. Cesium
-
131 is a radioactive isotope that can be
produced by the




ADVANCED MEDICAL ISOTOPE CORP
25
neutron bombardment of Barium
-
130 (Ba
-
130).
The brachytherapy seed form of Cesium
-
131 may
be used in surface, interstitial and intracavity applica
tions for tumors with known radio sensitivity.
The Company's product candidate is Proxcelan C
esium
-
131.
The Company markets the Proxcelan
Cesium
-
131 brachytherapy seed for the treatment of prostate cancer; brain c
ancer; lung cancer;
head and neck cancers; gynecological cancer: pelvic/abdominal ca
ncer; colorectal cancer, and
ocular melanoma. To pro
duce the Proxcelan seed, the purified Cesium
-
131 isotope is adsorbed
onto a ceramic core containing a gold X
-
ray marker. The Company also markets the GliaSite RTS
for the treatment of brain cancer, such as primary and
recurrent gliomas and metastic brain t
umors.
GliaSite RTS is a cleared balloon catheter device. T
he main components included in the GliaSite
RTS are the GliaSite Catheter Tray, GliaSite Access
Tray, Iotrex Solidifier and either Iotrex or Cesitr
ex
as the radiotherapy solution. The catheter tray
includes a GliaSite RTS catheter, two non
-
coring
needles, and two right anchoring clips. Cesitrex is the liquid fo
rm of Cesium
-
131 and can be used
in place of Iotrex, the liquid form of Iodine
-
125, in the Company's GliaSite RTS.
Oncosil Medical
Oncosil Me
dical (ASX:OSL) is an Australia based Life Sciences compa
ny that is developing a
noveltherapy device that implanted locally emits cancer killing
radiation into a tumor, called
OncoSil™.
The therapy showed favorable results in four Phase II clinical trials
in pancreatic and
primary liver
cancer and the company has recently filed for CE Mark appr
oval that is expected to
be announced
in early 2017
. The CE Mark is required to market and sell OncoSil
™ in the EU.
The
OncoSil™ therapy is an example of brachythera
py. The device consists of a mixture of very small
particles of silicon and phosphorus. When the
particles are placed in a nuclear reactor for ten days,
the phosphorus becomes radioactive. That
radioactivity is emitted as beta particles, which only
travel
about one centimeter through tissues




26
ADVANCED MEDICAL ISOTOPE CORP
Sirtex
(SRX.AX)
Sirtex Medical Limited is an Australia
-
based healthcare and medical device company, which
manufactures and distributes liver cancer treatments
utilizing small particle technology. The
Company's segments
are based on the regional markets it operates, which inc
lude Asia Pacific,
The Americas, and Europe, the Middle East and Africa (EMEA). The Company
's lead product is a
focused radiation therapy known as SIR
-
Spheres Y
-
90 resin microspheres, which is a radi
oactive
treatment for liver cancer. The treatment is called Selectiv
e Internal Radiation Therapy (SIRT) and
consists of a minimally invasive surgical procedure perfo
rmed by an interventional radiologist. The
SIR
-
Spheres microspheres lodge in the small bloo
d vessels of the tumor where they destroy it from
the inside over a short period while sparing the surroundin
g healthy tissue. It is available in more
than 40 countries and over 900 hospitals. The Company ha
s manufacturing and operations in the
United Stat
es, Germany and Singapore.
AB Science (AB.PA)
AB Science is a pharmaceutical company specializing
in the research, development and
commercialization of protein kinase inhibitors (PKIs),
a class of targeted proteins whose action are
key in si
gnaling pathway
s within cells. Its
programs target only diseases with high unmet medical
needs, often lethal with short term survival or rare or refracto
ry to previous line of treatment in
cancers, inflammatory diseases, and central nervous syste
m diseases, both in humans and animal
health
.
Its lead program Masitinib h
as been registered in the treatment of canine mast cell
tumors,
the most common cutaneous tumors in dogs, accounting for b
etween 7 and 21% of all canine
tumors.
In a randomized placebo
-
controlled Phase 3 clinical trial, 202 do
gs of different breeds were
treated with either masitinib (12.5mg/kg) or placebo. This
study demonstrated that masitinib is safe
and effective in the treatment of dogs with grade II o
r grade III cutaneous mast cell tumors.
In dogs
with non
-
resectable mast
cell tumors, masitinib was superior to placebo in ter
ms of time to tumor
progression (median of 173 days versus 75 days for placebo, p=0.
001), and overall survival time




ADVANCED MEDICAL ISOTOPE CORP
27
(median of 617 days versus 322 days for placebo, p=0.078).
Aratana Therapeutics
(PETX)
Aratana Therapeutics is a pet therapeutics company f
ocused on licensing, developing and
commercializing innovative therapeutics for dogs and cats
. Aratana believes that it can leverage
the investment in the human biopharmaceutical industry to b
ring therap
eutics to dogs and cats in
a capital and time efficient manner. The Company's pipeli
ne includes therapeutic candidates for
the potential treatment of pain, inappetence, viral disease
s, allergy, cancer and other serious
medical conditions.
Kindred Biosciences (KIN)
Kindred Biosciences is a pre
-
commercialization biopharmaceutical company focused on savi
ng and
improving the lives of pets. Its mission is to bring to pets
the same kinds of safe and effective
medicines that human family members enjoy. The Company
’s s t r a t e g y i s t o i d e n t i f y c o m p o u n d s
and targets that have already demonstrated safety and efficac
y in humans and to develop
therapeutics based on these validated compounds and targe
ts for dogs, cats and horses. The
Company has a deep pipeline of drugs and
biologics in development for animal
-
use indications
across many therapeutic classes.
Oasmia Pharmaceutical AB (OASM.ST)
Oasmia Pharmaceutical AB is a Sweden
-
based pharmaceutical company engaged in the field of
human and veterinary oncology. The Company’s
activities are divided into two segments: Human
Health and Animal Health. The Human Health segment spec
ializes in ovarian and breast cancer.
The Animal Health area focuses on developing cancer treatments for dogs. I
ts drugs portfolio
comprises six candidat
es: Paclical, Doxophos, Docecal and OAS
-
19, which are implemented in
human treatment, as well as Paccal Vet
-
CA1 and Doxophos Vet, introduced in cancer in dogs. T
he




28
ADVANCED MEDICAL ISOTOPE CORP
Company’s medicines are based on the patented XR
-
17 excipient, which forms micelles with water
-
soluble substances. Furthermore, It cooperates with Abbo
tt Laboratories, Pharmasyntez, Nippon
Zenyaku Kogyo and Medison Pharma. The Company is a parent of Oasmi
a Global Supplies AB and
Oasmia Animal Health AB.

so the remaining note holders are converting at a fixed price and locking up?

hopefully you will spread the word, every share outstanding is being sucked up by a group here just so you are aware

it cleared FDA earlier this year? Its for pets only, not humans. I only care about the pet therapy as its wrapping demonstrations now. plan is to have vet clinic$ use it and go from there forward....the device and isotope delivery are safe and effective in cats, completed a few months ago. Dogs started in May. Any clinic can sign on for cats, and awaiting dogs....it only takes 1 clinic to snowball this into $dollar range

lol its not a cure for cancer....its an effective treatment of tumor cancer that minimizes discomfort. Dog today gets blasted with beams and then does lots of chemotherapy and feels like crap, or, they simply get a single injection of Isopet and has 0 side effects for the same, or less overall cost. Which would you sign your pet up for?

? They issue convertible notes when cash is needed. That is the way pre-revenue biopharma's works. They get whatever they need on demand pretty much. Its these notes that create money/value for investors, who can catch stocks like RDGL under .01 as the noteholder drops off their load. Often the company is very much undervalued when a noteholder sells, which is the opportunity in pinky land. Usually noteholders hire market makers to artificially drop the price so they can convert as well. RDGL never should have gone to .0027. All forced.

These guys are planning to deploy Isopet at any moment. All it takes is 1 clinic to jump on its gangbusters from there.

can't be understated enough that recently the country saw many vet clinics adopt nuclear medicine for Strontium. RDGL's Isopet supercharges what Strontium does. These clinics are equipped to deploy RDGL rapidly. The demonstration phase is about complete here.

https://www.google.com/search?source=hp&ei=4xxVW7_hDLGHmwW1vbyIAw&q=strontium+90+pet+therapy&oq=strontium+90+pet+therapy&gs_l=psy-ab.3...1131.7435.0.7667.27.21.0.0.0.0.594.4005.0j3j7j2j1j1.14.0....0...1.1.64.psy-ab..13.13.3770.0..0j0i131k1j0i22i30k1j33i160k1j33i22i29i30k1.0.0hrp-fGY-d4

RadioGelTM is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.

https://globenewswire.com/news-release/2018/01/02/1277091/0/en/Advanced-Medical-Isotope-Corporation-ADMD-Announces-Corporate-Name-Change-to-Vivos-Inc-and-Ticker-Symbol-Change-to-RDGL.html

I read somewhere that once they inject this into the tumor, that it hardens and freezes in place, holding the radiation to the tumor without spreading elsewhere. I will have to find it again...its what makes the treatment work so well without toxicity to other organs or area.

Seems to me all systems a-go here as they shared cat data with VCA over the last few months, and are now sharing dog data which started in May and goes through November.

scroll to isopet

http://vhc.missouri.edu/small-animal-hospital/oncology/clinical-trials/current-clinical-trials/

one big report here:

http://healthdocbox.com/Brain_Tumor/67151607-Advanced-medical-isotope-corp.html

The 5% holders purchased immediately after this

Glad i bought 1.5m i will attempt some ceo update on how may treatments going. Life saving treatment only thing left is to make sure the drug doesnt spread toxicity out of the treatment area. Which it does not if on all accounts. Dosing is key

This is about to get silly

Even note holders have little to no stock. Explosively thin. Do you guys work on news from the ceo? The may teatment updates anticipated to drive this multiples upon multiples

This thing only went below .01 this month sparingly and those got picked up by sched d and g. Its only The beginning of an easy 500 ticks up with only 90 ticks down potential. The last PR talks about data being built as baseline for VCA Marketing and there are likely many small private vet clinics on boarding now Or simply buying stock

that is smoking...those animal trials were successfully done in May

attitude about to turn positive here for a good while it seems could be multi month runner

you guys know what you are doing I like it....ACSM has to cover big here.

who's vca and how do you know?

An asian d filer is always good news

https://www.prosek.com/unboxed-thoughts/another-difference-between-d-and-g-is-more-than-just-the-obvious/

ascm should know this has viral written all over it. 3 or 4 vets onboarding quickly turns into 30 or 40. who's doing all of this buying? not IHUB or any group

considering they just started selling Isopet in the last few days to over 300 Vets there is a good chance you don't know what you are talking about. These people, like most, don't look at a chart. My guess is Asian vets are about to be marketed as well based on the early July filing.

http://find.vetspecialists.com/search_results?page=1&ttid=4&tid=+&location_value=

Was just a preliminary file. I wonder who the strategic partners are

quite a bit

http://find.vetspecialists.com/search_results?page=1&ttid=4&tid=+&location_value=

If they are making their commercial push and veterinarians are liking it then this may be why its moving

ACSM in trouble on yet another ticker.

headed to Asia is the idea with this purchase IMO

Residence or business address; Flat H, 13/F, Block 10, Park Island, Hong Kong

it looks to me that they sold 100 producing wells that did $7M rev last 12 months, and are left with about 50 well bores to bring online.

Would think they can get up to $3M or so in rev. But, those guys wouldn't have assumed the $36M in debt unless they thought energy prices were going to rise, hoping the $7M in rev they acquired turns into $10M or more annually. Have to figure a solid $4M or $5M rev company here

what I come up with is they will be getting about $1M in royalties per year cash, have $4M debt left, 15M O/S and brand new leases to work. $15M in NOLS. Whatever those new leases can produce is what the worth is here...

nice site http://www.supremesweetsinc.com/

looks like about a $10M deal? $5M promisarry note and 20% of UHLN https://www.nasdaq.com/press-release/us-highland-cruzani-announces-the-completion-of-supreme-sweets-acquisition-20180711-00344

here we go health insurers breaking past all time highs at the moment...EHTH should break its all 12 month $28 high easily shortly and press toward its all time high of around $55 into end of 2018.

my article brings to light information that even EHTH did not know or address yet with analysts in terms of amount of commission rates increases moving forward...I've pinged all of the analysts to bring it up on the July 26th earnings call and I've emailed the EHTH CEO to get on it.

heading toward all time high whole sector is breaking all time highs and ehth has what it takes to get to $50 now

Price Targets $50, then $100, then $200

https://seekingalpha.com/article/4186073-ehealth-medicare-commissions-grow-company

at the end of the day, I am trying to make money with the company, and also catch the CEO attention...would like to consult for them....

I think its going to take off very shortly...EHTH should be coming out with a PR on the Q2 which is July 26th...I'm hoping they are ready to announce 2019 preview....

13M S.A. readers...42M pageview monthly...hoping to get traction